Molecular Formula | C20H22N4 |
Molar Mass | 318.42 |
Density | 1.169±0.06 g/cm3(Predicted) |
Boling Point | 544.8±42.0 °C(Predicted) |
Solubility | DMSO: ≥ 42 mg/mL |
pKa | 10.13±0.29(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
In vitro study | WAY-262611 has the most potent activity in the primary assay, low kinase inhibition potential, and high solubility. |
In vivo study | WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wnt β -catenin pathway and most likely through inhibition of Dkk-1. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.141 ml | 15.703 ml | 31.406 ml |
5 mM | 0.628 ml | 3.141 ml | 6.281 ml |
10 mM | 0.314 ml | 1.57 ml | 3.141 ml |
5 mM | 0.063 ml | 0.314 ml | 0.628 ml |